
Milestone Pharmaceuticals Inc. (NASDAQ:MIST – Free Report) – Equities researchers at HC Wainwright raised their FY2026 earnings estimates for Milestone Pharmaceuticals in a report issued on Monday, November 16th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($0.85) per share for the year, up from their previous estimate of ($0.86). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ Q4 2026 earnings at ($0.26) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.29) EPS, FY2029 earnings at ($0.11) EPS and FY2030 earnings at $0.47 EPS.
MIST has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Monday, October 12th. Cantor Fitzgerald initiated coverage on Milestone Pharmaceuticals in a research report on Thursday, August 20th. They issued an “overweight” rating and a $3.00 target price for the company. Wall Street Zen raised Milestone Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday. Finally, Piper Sandler reduced their price target on Milestone Pharmaceuticals to $3.00 and set an “overweight” rating on the stock in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Milestone Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.83.
Check Out Our Latest Analysis on MIST
Milestone Pharmaceuticals Stock Performance
Shares of MIST stock opened at $0.41 on Wednesday. Milestone Pharmaceuticals has a twelve month low of $0.36 and a twelve month high of $3.06. The company has a debt-to-equity ratio of 3.25, a quick ratio of 7.92 and a current ratio of 6.27. The stock’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $1.29.
Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Milestone Pharmaceuticals had a negative return on equity of 435.88% and a negative net margin of 1,860.76%. The company had revenue of $2.96 million during the quarter, compared to analysts’ expectations of $1.00 million.
Hedge Funds Weigh In On Milestone Pharmaceuticals
Hedge funds have recently modified their holdings of the business. HighTower Advisors LLC raised its position in shares of Milestone Pharmaceuticals by 100.0% in the 2nd quarter. HighTower Advisors LLC now owns 20,000 shares of the company’s stock worth $27,000 after acquiring an additional 10,000 shares in the last quarter. Valeo Financial Advisors LLC lifted its stake in shares of Milestone Pharmaceuticals by 12.2% in the 3rd quarter. Valeo Financial Advisors LLC now owns 146,699 shares of the company’s stock valued at $127,000 after purchasing an additional 16,000 shares during the period. Bay Rivers Group boosted its position in shares of Milestone Pharmaceuticals by 55.9% during the 2nd quarter. Bay Rivers Group now owns 46,633 shares of the company’s stock valued at $62,000 after purchasing an additional 16,722 shares in the last quarter. Waterloo Capital L.P. bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $40,000. Finally, Guardian Wealth Advisors LLC NC boosted its position in shares of Milestone Pharmaceuticals by 21.1% during the 2nd quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after purchasing an additional 59,200 shares in the last quarter. Institutional investors and hedge funds own 86.18% of the company’s stock.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing treatments for cardiovascular conditions. Its work centers on therapies intended to give patients and caregivers options for managing acute heart rhythm episodes outside of a clinical setting. The company’s lead product is etripamil, a short-acting calcium channel blocker formulated as a nasal spray. It is designed for self-administration to treat episodes of paroxysmal supraventricular tachycardia, a condition involving sudden episodes of abnormally fast heart rate.
See Also
- Five stocks we like better than Milestone Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
